This article discusses peptides as research compounds. It is not medical advice.
A clinician I spoke with recently mentioned that patients on GLP-1 receptor agonists often ask whether rapid weight loss will weaken their bones. The question is not trivial. Semaglutide, tirzepatide, and retatrutide produce substantial reductions in body mass, and body mass is a known determinant of bone mineral density. Yet the relationship between GLP-1-driven weight loss and skeletal health remains unsettled in the published literature.
Researchers have examined bone turnover markers, fracture incidence, and bone mineral density in people using these compounds. A 2022 review in The Lancet Diabetes & Endocrinology noted that GLP-1 receptor agonists may influence bone metabolism through both weight-dependent and weight-independent pathways. The authors cautioned that fracture data from cardiovascular outcomes trials were not designed to capture osteoporosis-related events. This gap leaves room for active investigation.
What this sub-niche covers
The sub-niche of GLP-1 weight loss and bone health sits at the intersection of endocrinology, osteoporosis research, and metabolic pharmacology. It asks whether pharmacologically induced weight reduction protects skeletal integrity, harms it, or acts neutrally. The question matters because obesity itself is associated with higher bone mineral density, partly due to mechanical loading and partly due to hormonal factors. When that loading disappears quickly, bone may adapt in ways that are not yet fully understood.
Researchers in this area also study whether GLP-1 receptor agonists have direct effects on bone cells. Preclinical work has identified GLP-1 receptors on osteoblasts and osteoclasts, though the functional significance in humans is unclear. A 2019 trial of liraglutide in type 2 diabetes found no significant change in bone mineral density over 26 weeks, but liraglutide produces less weight loss than semaglutide. The dose-response relationship for bone outcomes has not been mapped.
Compounding the picture, many patients using GLP-1 drugs for weight loss are also using other research peptides. AOD-9604, a fragment of human growth hormone, is sometimes stacked with semaglutide or tirzepatide in research settings. The AOD-9604 and tirzepatide stack has drawn FDA scrutiny for unapproved use, but its bone effects are not established. Similarly, CJC-1295 and hexarelin, which stimulate growth hormone secretion, could theoretically influence bone turnover, yet no long-term bone data exist for these combinations.
Key compounds in this area
Semaglutide is the most studied GLP-1 receptor agonist for weight loss. Its effects on bone have been examined in post hoc analyses of the STEP trials. A 2021 analysis of STEP 1 and STEP 4 found no increase in fracture incidence among participants treated with semaglutide compared with placebo, but the trials were not powered for rare skeletal events. The follow-up duration of 68 weeks may be too short to detect changes in bone mineral density that accumulate over years.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than semaglutide. A 2023 analysis of SURMOUNT-1 reported no signal for increased fractures over 72 weeks. However, the same analysis noted that bone mineral density was not measured. Retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, is in late-stage development. Its bone effects are unknown because phase 2 trials did not include bone endpoints.
AOD-9604 is a peptide fragment of the C-terminus of human growth hormone. It was originally investigated for obesity and cartilage repair. A 2020 review of AOD-9604 research found no published studies on bone mineral density or fracture risk. The compound is often discussed alongside GLP-1 agonists in research communities, but the evidence base for skeletal outcomes is essentially absent. CJC-1295 and hexarelin are growth hormone secretagogues. Growth hormone is known to influence bone remodeling, so researchers have hypothesized that these peptides could offset any negative bone effects of rapid weight loss. No clinical trial has tested that hypothesis.
What the research consensus looks like
The research consensus, if one can be called that, is that GLP-1 receptor agonists do not appear to increase fracture risk in the short term. A 2022 meta-analysis of 27 randomized trials found no significant difference in fracture incidence between GLP-1 users and comparators. The authors noted that the confidence intervals were wide, reflecting the rarity of fractures in trial populations. Most trials enrolled people with type 2 diabetes, not people using the drugs solely for weight loss.
Bone mineral density data are scarcer. A 2023 prospective study of 50 adults without diabetes who used semaglutide for weight loss reported a small but statistically significant decline in total hip bone mineral density after 12 months. The decline was within the range expected for the amount of weight lost. The study did not include a control group, so causality could not be established. Another 2023 study using dual-energy X-ray absorptiometry in 40 patients found no change in lumbar spine bone density after 6 months of semaglutide.
Researchers generally agree that weight loss of any kind, whether from diet, surgery, or medication, is associated with a transient increase in bone turnover and a modest decrease in bone mineral density. The clinical significance of this phenomenon is debated. Some argue that the metabolic benefits of weight loss outweigh any small skeletal risk. Others point to the increased fracture risk observed after bariatric surgery, which produces more rapid and larger weight loss than GLP-1 drugs. The semaglutide versus retatrutide comparison in FDA discussions has not yet included bone safety as a primary endpoint.
Where the active research is
Active research is moving in several directions. One line of work examines whether GLP-1 receptor agonists have direct anabolic effects on bone that could offset weight-loss-related resorption. A 2021 study in mice found that semaglutide increased osteoblast activity and reduced osteoclast activity independent of body weight. Whether this translates to humans is unknown. A 2024 phase 2 trial is measuring bone turnover markers in adults using semaglutide for weight loss, with results expected in 2025.
Another active area is the interaction between GLP-1 drugs and osteoporosis medications. Patients who are already taking bisphosphonates or denosumab may experience different bone responses to weight loss. A 2023 retrospective cohort study using insurance claims found no increase in fracture risk among GLP-1 users who were also on osteoporosis therapy, but the follow-up was only one year. Prospective studies with longer follow-up are needed.
Researchers are also investigating whether the rate of weight loss matters more than the total amount. A 2022 analysis of the STEP trials found that participants who lost weight more rapidly in the first 20 weeks had slightly greater declines in bone mineral density at 68 weeks, though the differences were not statistically significant. This has led to interest in whether slower titration schedules could preserve bone. The semaglutide microdosing research touches on this question, though bone outcomes have not been reported in those protocols.
Where the gaps are
The gaps in the literature are substantial. No randomized controlled trial has been designed specifically to assess fracture risk or bone mineral density as a primary outcome for any GLP-1 receptor agonist used for weight loss. Existing data come from secondary analyses of trials designed for cardiovascular or glycemic endpoints. Those trials typically exclude people with osteoporosis or a history of fragility fractures, which limits generalizability.
Long-term data beyond two years are almost nonexistent. Weight loss from GLP-1 drugs is often maintained for years, but bone adaptation may occur over a longer horizon. The STEP 5 trial followed participants for two years, but bone mineral density was not measured. Observational studies using administrative databases have reported conflicting results on fracture risk, likely due to confounding by indication and differences in baseline fracture risk.
Another gap concerns combination use of GLP-1 drugs with other research peptides. AOD-9604, CJC-1295, and hexarelin are frequently discussed in online forums as adjuncts to semaglutide or tirzepatide, but no published study has examined their combined effects on bone. The AOD-9604 and CJC-1295 stack has been studied for body recomposition, not for skeletal outcomes. Researchers who work with these compounds in preclinical settings have an opportunity to fill a clear evidence void.
Finally, there is a gap in understanding how GLP-1 drugs affect bone in specific populations: postmenopausal women, older adults with sarcopenia, and people with type 2 diabetes who already have higher fracture risk. A 2023 editorial in Osteoporosis International called for dedicated bone safety trials in these groups. Until such trials are completed, the question of whether GLP-1 weight loss protects against osteoporosis will remain open.
If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
Common questions
Does semaglutide cause bone loss?
Short-term studies suggest that semaglutide-induced weight loss is associated with a small decline in bone mineral density at the hip, similar to what is seen with other forms of weight loss. A 2023 prospective study of 50 adults reported a statistically significant decrease in total hip bone mineral density after 12 months of semaglutide use. However, the change was within the expected range for the amount of weight lost, and no increase in fractures has been observed in clinical trials. The long-term significance of this bone density decline is not known.
Can GLP-1 drugs protect against osteoporosis?
There is no direct evidence that GLP-1 receptor agonists protect against osteoporosis. Some preclinical studies suggest that GLP-1 signaling may have anabolic effects on bone, but human data are lacking. The weight loss produced by these drugs could theoretically reduce mechanical loading on bone, which might increase resorption. At present, researchers do not consider GLP-1 drugs to be bone-protective agents.
What is AOD-9604 and does it affect bone?
AOD-9604 is a peptide fragment of human growth hormone that was investigated for obesity and cartilage repair. No published studies have examined its effects on bone mineral density or fracture risk. It is sometimes discussed alongside GLP-1 drugs in research settings, but the evidence base for skeletal outcomes is absent. Researchers should treat any bone-related claims about AOD-9604 as unsubstantiated.
Are there any clinical trials measuring bone density in semaglutide users?
Yes, at least one phase 2 trial is currently measuring bone turnover markers in adults using semaglutide for weight loss, with results expected in 2025. However, no completed randomized controlled trial has used bone mineral density or fracture incidence as a primary endpoint for semaglutide. Existing data come from secondary analyses of trials designed for other purposes. Dedicated bone safety trials have been called for by osteoporosis researchers.
Should people with osteoporosis avoid semaglutide?
Clinical trials of semaglutide have generally excluded people with known osteoporosis or a history of fragility fractures, so direct evidence is limited. Observational studies have not shown a clear increase in fracture risk among GLP-1 users, but confounding is possible. Patients with osteoporosis who are considering semaglutide for weight loss should discuss the risks and benefits with a physician. This article does not provide medical advice.
This article discusses peptides as research compounds. It is not medical advice.